Entera Bio Ltd (NASDAQ:ENTX)., an Israel-based biotechnology firm, has submitted a new filing with the U.S. Securities and Exchange Commission (SEC) on Friday. The filing includes legal documents related to the company's securities.
According to the SEC Form 8-K filed on January 10, 2025, Entera Bio provided Exhibit 5.1, which contains the legal opinion of Herzog Fox & Neeman, and Exhibit 23.1, which includes the consent of the same legal firm. These exhibits are related to the company's securities and do not constitute an offer to sell or a solicitation of an offer to buy any securities.
Entera Bio, listed on the Nasdaq Capital Market under the ticker symbol NASDAQ:ENTX, is in the biological products industry, excluding diagnostic substances. The company's ordinary shares have a par value of NIS 0.0000769.
The specifics of the legal opinion and consent were not detailed in the press release statement. The filing is a routine disclosure that publicly traded companies are required to make when legal opinions regarding their securities are issued.
This filing is part of Entera Bio's ongoing compliance with SEC regulations and does not necessarily indicate any material changes to the company's financial position or operations. It is a standard procedure for companies to file such documents with the SEC to ensure transparency and adherence to legal and regulatory requirements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.